Document is current

Article History

Received: 13 December 2025

Accepted: 27 July 2026

First Online: 3 August 2026

Declarations

Ethics approval and consent to participate: The study complied with the Declaration of Helsinki and was approved by the Hungarian National Ethics Committee (ETT-TUKEB; BMEÜ/3788–1/2022/EKU). Prior to participation, all participants received thorough information about the study and provided written informed consent.

Consent for publication: Not applicable.

Competing interests: LG-T reports a relationship with AbbVie that includes: speaking and lecture fees. GN reports a relationship with Miltenyi, AstraZeneca, and Richter that includes consulting or advisory services. GN reports a relationship with AbbVie, Eli Lilly, Merck Sharp & Dohme, Swedish Orphan Biovitrum, GSK, Pfizer, Swixx, Amgen, UCB, Janssen, AstraZeneca, and Takeda that includes speaking and lecture fees. GN reports a relationship with Biotest that includes travel reimbursement. GK, GS, and GN report a relationship with the Executive Board of the Hungarian Association of Rheumatology that includes board membership. GS reports a relationship with the Executive Board of the Hungarian Society of Allergology and Clinical Immunology that includes board membership. Gyorgy Nagy reports a relationship with the European Alliance of Associations for Rheumatology congress committee member that includes board membership. GSCH reports a relationship with Bristol Myers Squibb Company, Cabaletta, Janssen Biotech, Kyverna, Miltenyi, and Novartis that includes speaking and lecture fees. Other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.